Regorafenib (BAY 73-4506)

製品コードS1178 別名:Fluoro-Sorafenib

Regorafenib (BAY 73-4506)化学構造

分子量(MW):482.82

Regorafenib (BAY 73-4506)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR1、VEGFR2、VEGFR3、PDGFR-β、Kit、RETとRaf-1に作用する時のIC50値が13 nM、4.2 nM、46 nM、22 nM、7 nM、1.5 nMと2.5 nMにそれぞれ分かれることです。

サイズ 価格(税別)  
JPY 27888.00
JPY 19920.00
JPY 34860.00
JPY 78020.00
JPY 161020.00

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Regorafenib (BAY 73-4506)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR1、VEGFR2、VEGFR3、PDGFR-β、Kit、RETとRaf-1に作用する時のIC50値が13 nM、4.2 nM、46 nM、22 nM、7 nM、1.5 nMと2.5 nMにそれぞれ分かれることです。
ターゲット
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
体外試験

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B M2Lqc2Fxd3C2b4Ppd{BCe3OjeR?= NGfteYoy6oDVNdMg{txO NXPnRYF{PDhiaB?= MmO1bY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkLDNlY{Ojl4MEi=
PLC/PRF/5  MoO1RZBweHSxc3nzJGF{e2G7 MUix5qCUPcLizszN NG[xZ3E1QCCq MXzpcohq[mm2czDj[YxtKGe{b4f0bC=> NIL3b3AzPjN{OU[wPC=>
HepG2  NUS4TI1XSXCxcITvd4l{KEG|c3H5 NYP4cZpbOeLCk{ZCpO69VQ>? MXm0PEBp M2DIcYlvcGmkaYTzJINmdGxiZ4Lve5Rp MmDCNlY{Ojl4MEi=
HEK293 M336eWZ2dmO2aX;uJGF{e2G7 M{LlVVAvPeLCid88US=> MV2yM|QwPiCq NF3ZdG1z\WS3Y3XzJGdTWDd6IHX4dJJme3Orb36= M{jp[FI2QDV6MEOy
GEO NFzQXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHod3cxNjBzLUKwJO69VQ>? NW\nOY5jQTZiaB?= M1j3eWROW09? MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX6yOVg{QDN7MR?=
SW48 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSwMlAyNTJyIN88US=> MYq5OkBp NEHqcJdFVVOR NIjYSGFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2e0bFI2QDN6M{mx
HT29 NHu2cHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILlZ2cxNjBzLUKwJO69VQ>? NELObIo6PiCq Ml;oSG1UVw>? NWm2XJFmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3nSdlI2QDN6M{mx
SW480 NEe3[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjZeY8xNjBzLUKwJO69VQ>? MVG5OkBp MmfZSG1UVw>? NU\TN|k6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUmyOVg{QDN7MR?=
SW620 M3fORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\LV|AvODFvMkCg{txO M2fUdlk3KGh? MnXPSG1UVw>? MnvibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUSyOVg{QDN7MR?=
HCT116 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CzT|AvODFvMkCg{txO MnHWPVYhcA>? M4S4V2ROW09? MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGiwO5ozPTh|OEO5NS=>
LOVO NUm5UGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMlAyNTJyIN88US=> MlrqPVYhcA>? NVvJSVE5TE2VTx?= MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlexNlU5Ozh|OUG=
HCT150 NFfYWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\QWYs6OC5yMT2yNEDPxE1? NV;zTopxQTZiaB?= M3PTPWROW09? MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4\vc|I2QDN6M{mx
SW48-CR NV7DepVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzzNE4xOS1{MDFOwG0> NVPaZXF4QTZiaB?= NHXKOZhFVVOR MoXubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWWyOVg{QDN7MR?=
GEO-CR NY\NWXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP4NE4xOS1{MDFOwG0> MnnFPVYhcA>? NF\DZ2pFVVOR MoPIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWWyOVg{QDN7MR?=
KB-31 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED0SodKSzVyPUWuOeKyOC5|IH7N MnnhNlU4PTN|NkG=
KB-G2 NX;sUFlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEKyWWpKSzVyPUmuNeKyOC5zIH7N Mne5NlU4PTN|NkG=
LLC-PK1 NYjDc|NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13tdWlEPTB;NEKuNOKyOy5{IH7N M3TvTlI2PzV|M{[x
LLC-PK1/MRP2 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4N|hSUUN3ME24Nk41yrF{Lkegcm0> NFfpN2IzPTd3M{O2NS=>
HEK293 NHP5SWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLwU4tnUUN3ME2xNU4xyrFzLkKgcm0> NUTicW9WOjV5NUOzOlE>
HEK293/OATP1B1 NGjHWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\aOoZKSzVyPU[uNuKyOC5|IH7N M{jjdVI2PzV|M{[x
HROC18 MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\TOHZXUUN3ME2xMlMh|ryP NXP5R5JLOjV|MEm5NVQ>
HROC24 NHLhZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLMTWM2OD12Lk[g{txO NUP2NFFpOjV|MEm5NVQ>
HROC43 NI\G[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTVwMzFOwG0> M{DhU|I2OzB7OUG0
HROC46 NY\2S5QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[1ZmlEPTB;Mj60JO69VQ>? NWPqZm5HOjV|MEm5NVQ>
RJ345 M4L3[2Z2dmO2aX;uJGF{e2G7 NWLORlFQOC53L{Wg{txO Mo\5NlQhcA>? NGf0dWlFVVOR MVzpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= NH31SHYzPTJ3M{m5OC=>
RJ348 NGny[IRHfW6ldHnvckBCe3OjeR?= MUWwMlUwPSEQvF2= NVLFOIV{OjRiaB?= M2GzU2ROW09? MYLpcohq[mm2czD0bIUh[2WubDDtbYdz[XSrb36= NI[0[24zPTJ3M{m5OC=>
MCF-7 NYrCTIplTnWwY4Tpc44hSXO|YYm= NX2wW2xqOC53L{Wg{txO MoTWNlQhcA>? MVnEUXNQ M2r2RolvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> MYmyOVI2Ozl7NB?=
MDA-MB-231 NH\I[5lHfW6ldHnvckBCe3OjeR?= MVKwMlUwPSEQvF2= NEXjS|AzPCCq MmfESG1UVw>? M3;QT4lvcGmkaYTzJJRp\SClZXzsJI1q\3KjdHnvci=> NXjmUYt6OjV{NUO5PVQ>
HT15 NUXTPZBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nZW|EuOjBizszN MWG0PEBp NHvhNIdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlvsNlUxPzFyMUi=
DLD1 NH72ZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[xMVIxKM7:TR?= M{HRXFQ5KGh? NYTMfmprcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXqyOVA4OTBzOB?=
HT-29 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP2N|RyOS1{MDFOwG0> MVO0PEBp M{P2eYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnvtNlUxPzFyMUi=
Hct-116 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzKeXoyNTJyIN88US=> MnSxOFghcA>? MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NG[1NIszPTB5MUCxPC=>
HT15 NGrVPJZCeG:ydH;zbZMhSXO|YYm= NYD1WppzOS1zMDFOwG0> MoLtOFghcA>? MlrUbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2WyXVI2ODdzMEG4
DLD1 NGjTR3dCeG:ydH;zbZMhSXO|YYm= NVS3PWRuOS1zMDFOwG0> M4fNPFQ5KGh? M3\GZolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MW[yOVA4OTBzOB?=
HT-29 NHXMfHdCeG:ydH;zbZMhSXO|YYm= MXexMVExKM7:TR?= NE[0Nok1QCCq MlrybY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{nxb|I2ODdzMEG4
Hct-116 MYPBdI9xfG:|aYOgRZN{[Xl? M{fVUFEuOTBizszN NGTC[GU1QCCq MnWxbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mmi4NlUxPzFyMUi=
GBM5 MnntRZBweHSxc3nzJGF{e2G7 NEnZUGwxNjYkgKOxMlDjiIoQvF2= NYLwdWpMOjRiaB?= MkfoSG1UVw>? NWjRdVZbcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MUSyOFkyOTJzNR?=
GBM6 NI\WUXZCeG:ydH;zbZMhSXO|YYm= NYq2eJpMOC534pETNU4x6oDLzszN MYKyOEBp NIfMW|JFVVOR M{DP[IlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> NWnpVYM3OjR7MUGyNVU>
GBM12 NHjaXXBCeG:ydH;zbZMhSXO|YYm= NF;YbVUxNjYkgKOxMlDjiIoQvF2= MoTlNlQhcA>? M2rQ[WROW09? MmDrbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo M4Lj[FI1QTFzMkG1
GBM14  NUPYVWYySXCxcITvd4l{KEG|c3H5 M2W0VlAvPeLCk{GuNQKBkc7:TR?= NWfQcJJWOjRiaB?= M4HxSmROW09? NES1eo9qdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> M2\qUVI1QTFzMkG1
Hep3B M1r6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nER|HjiJN{LkZCpO69VQ>? MYOyOE81QC95MjDo MV7pcohq[mm2czDj[YxtKGe{b4f0bC=> NGnDe|IzPDh6NUi5NC=>
PLC/PRF/5  NEnrZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXix5qCUOi53wrFOwG0> NUTMT2NPOjRxNEivO|IhcA>? NYPlPYN7cW6qaXLpeJMh[2WubDDndo94fGh? M4nDTVI1QDh3OEmw
HepG2  NYe4dotQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rOUlHjiJN{LkZCpO69VQ>? MUiyOE81QC95MjDo MYLpcohq[mm2czDj[YxtKGe{b4f0bC=> NFqxOlUzPDh6NUi5NC=>
HCT116  NEXuTlBHfW6ldHnvckBCe3OjeR?= M3\pSVExNzJyL{SwJO69VQ>? M33WOVI1KGh? NGTQ[45qdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:wIHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M{C0TVI1PzZ|NkGx
Lim2405 MkDUSpVv[3Srb36gRZN{[Xl? M2PycFQxKM7:TR?= M2G1XVI1KGh? NVrGSXJ1cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NULtcZVtOjR5NkO2NVE>
LoVo MmGzSpVv[3Srb36gRZN{[Xl? M{C2PFQxKM7:TR?= MnXuNlQhcA>? MnfVbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M3OwTFI1PzZ|NkGx
Lim1215 NFzobYxHfW6ldHnvckBCe3OjeR?= M3fhflQxKM7:TR?= M4DCOlI1KGh? NHrPW5VqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MlXiNlQ4PjN4MUG=
SW48 MkewSpVv[3Srb36gRZN{[Xl? NHvhdYM1OCEQvF2= MXWyOEBp M4\ubYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M4XEUlI1PzZ|NkGx
RKO  NEG4UJpHfW6ldHnvckBCe3OjeR?= MXO0NEDPxE1? NXLjUpRkOjRiaB?= MVzpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NYTQeVlmOjR5NkO2NVE>
SW837 MnHvSpVv[3Srb36gRZN{[Xl? MWK0NEDPxE1? M3vtN|I1KGh? MVjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M1fG[|I1PzZ|NkGx
SW1463 NHrPepFHfW6ldHnvckBCe3OjeR?= M2jTcVQxKM7:TR?= MYSyOEBp MXfpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MkPzNlQ4PjN4MUG=
SW480 M{XIPGZ2dmO2aX;uJGF{e2G7 MlTkOFAh|ryP MlrRNlQhcA>? M1[zWYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NGLGOXUzPDd4M{[xNS=>
Vaco432 MofOSpVv[3Srb36gRZN{[Xl? NHXwPIY1OCEQvF2= MkjKNlQhcA>? M4KyPYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MkLQNlQ4PjN4MUG=
Vaco400 NFjLTJdHfW6ldHnvckBCe3OjeR?= Mn[yOFAh|ryP NIq2e4szPCCq NE\FOZJqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MWmyOFc3OzZzMR?=
DLD1 NWPObZBiTnWwY4Tpc44hSXO|YYm= Mn7SOFAh|ryP NXrZToFOOjRiaB?= MWHpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> Mlu5NlQ4PjN4MUG=
HT29  NETSTm5HfW6ldHnvckBCe3OjeR?= MnLCOFAh|ryP NYrKW|hxOjRiaB?= NWCwdHk3cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MoL5NlQ4PjN4MUG=
PLC/PRF/5  NE\4UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBNncy6oDVNdM1US=> NHzSW5kzPC92OD:3NkBp MnX2bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NHnEOHczOzF4OUG0PC=>
HepG2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DNT|HjiJN3wsXN Mn64NlQwPDhxN{KgbC=> NXraU4U5cW6qaXLpeJMh[2WubDDndo94fGh? NU\TZWt[OjNzNkmxOFg>
Hep3B  NXPNNFg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nNR|HjiJN3wsXN NILjdIEzPC92OD:3NkBp M2i0[olvcGmkaYTzJINmdGxiZ4Lve5Rp MnflNlMyPjlzNEi=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
細胞試験: [1]
+ 展開
  • 細胞株: GIST 882 and TT cells
  • 濃度: 5 nM-10 μM
  • 反応時間: 96 hours
  • 実験の流れ: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • 製剤: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • 投薬量: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL (suspension)

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 482.82
化学式

C21H15ClF4N4O3

CAS No. 755037-03-7
保管
別名 Fluoro-Sorafenib

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

VEGFR信号経路図

VEGFR Inhibitors with Unique Features

相関VEGFR製品

Tags: Regorafenib (BAY 73-4506)を買う | Regorafenib (BAY 73-4506) ic50 | Regorafenib (BAY 73-4506)供給者 | Regorafenib (BAY 73-4506)を購入する | Regorafenib (BAY 73-4506)費用 | Regorafenib (BAY 73-4506)生産者 | オーダーRegorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506)化学構造 | Regorafenib (BAY 73-4506)分子量 | Regorafenib (BAY 73-4506)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID